Medical Office Real Estate in Philadelphia, PA

Cap rates for medical office properties in Philadelphia vary by submarket, property class, and occupancy levels. The overall Philadelphia market average cap rate is approximately 6.5%. Class A properties typically trade at lower cap rates than value-add opportunities.

Healthcare demand is driven by demographics (aging population) and medical necessity rather than economic conditions. People require medical care regardless of the economic environment, and the shift toward outpatient care continues to accelerate. Medical tenants have long lease terms, high renewal rates, and significant buildout costs that make relocation unattractive. These factors combine to produce stable occupancy and rent collection even during economic downturns.

On-campus MOBs are located on or immediately adjacent to a hospital campus, benefiting from direct referral traffic, shared services, and the hospital system brand. They typically command lower cap rates (4.5-5.5%) due to perceived stability. Off-campus MOBs are standalone or in medical parks away from hospitals, typically trading at higher cap rates (5.5-7.0%) but offering potentially higher returns. Off-campus properties may have more diverse tenant bases and less dependence on a single health system.

Philadelphia offers 100-200 basis points higher cap rates than comparable New York assets, providing a meaningful yield premium. The metro benefits from proximity to New York (90 minutes by train) while maintaining its own deep employment base. Life sciences, healthcare, and education institutions provide recession-resistant demand that New York's more finance-dependent economy does not always match. However, Philadelphia's total market liquidity and appreciation potential are more modest than New York.

The University of Pennsylvania, Drexel, Temple, and Jefferson health systems generate enormous research funding that spins off into commercial lab and office demand. University City's uCity Square and Schuylkill Yards developments are adding millions of square feet of purpose-built lab space. The metro is the second-largest cell and gene therapy hub in the US after the Boston-Cambridge corridor. Major pharma companies including GSK, Merck, and AstraZeneca maintain significant operations in the region.